Cantor Fitzgerald Predicts ESPR FY2025 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska forecasts that the biopharmaceutical company will post earnings per share of $0.05 for the year. Cantor Fitzgerald has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $51.63 million for the quarter, compared to analysts’ expectations of $55.44 million. During the same quarter in the previous year, the business earned ($0.37) earnings per share.

A number of other equities research analysts also recently commented on the company. The Goldman Sachs Group assumed coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Thursday. JMP Securities reiterated a “market outperform” rating and set a $7.00 price objective on shares of Esperion Therapeutics in a research report on Thursday. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $7.25.

Esperion Therapeutics Stock Down 5.5 %

Shares of ESPR stock opened at $2.08 on Wednesday. The stock has a market cap of $409.84 million, a P/E ratio of -3.25 and a beta of 1.03. The company’s fifty day simple moving average is $2.46 and its two-hundred day simple moving average is $2.18. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Boomfish Wealth Group LLC boosted its holdings in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 5,102 shares during the period. Foundations Investment Advisors LLC lifted its position in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 9,872 shares during the last quarter. Xponance Inc. purchased a new stake in shares of Esperion Therapeutics during the second quarter valued at $28,000. Traphagen Investment Advisors LLC bought a new position in shares of Esperion Therapeutics in the third quarter worth about $27,000. Finally, Mackenzie Financial Corp increased its stake in Esperion Therapeutics by 104.8% in the 2nd quarter. Mackenzie Financial Corp now owns 35,254 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 18,036 shares during the period. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.